Nachrichten zur Bristol-Myers Squibb Co Aktie

Bristol-Myers Squibb: A Potential Comeback In Healthcare

…

Albumin-gebundenes Paclitaxel von Kexing Biopharm erhält EU-Marktzulassung

Kexing Biopharm: Shenzhen, China (ots/PRNewswire) - Am 28. Juli 2024 gab Kexing Biopharm die Genehmigung der Europäischen Kommission für Apexelsin®…

Analyst Report: Bristol-Myers Squibb Co.

…

Is Bristol Myers Squibb a Good Dividend Stock to Buy Now? @themotleyfool #stocks $BMY $PFE

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…

Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…

Bristol-Myers Squibb Earnings Reinforces Our Thesis

…

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

…

Why Bristol Myers Squibb Jumped Nearly 10% on Friday

…

Why Bristol Myers Squibb Jumped Nearly 10% on Friday @themotleyfool #stocks $BMY

The pharmaceutical company is faring far better than most investors were anticipating at this point.…

Why Bristol Myers Squibb Jumped Nearly 10% on Friday

The pharmaceutical company is faring far better than most investors were anticipating at this point.…

Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript

BMY earnings call for the period ending June 30, 2024.…

Bristol Myers Squibb Witnesses Strong Demand For Newer Drugs As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast

…

Bristol-Myers Squibb stock gains after raising full-year guidance By Investing.com

Bristol-Myers Squibb stock gains after raising full-year guidance…

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs

The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into…

June PCE, Bristol Myers Squibb earnings: What to watch Friday

Asking for a Trend Host Josh Lipton breaks down what to watch on Friday, July 26th. Personal Consumption Expenditures (PCE)…

Global Musculoskeletal Market Size is Expected To Hold a Significant Share By 2033 | CAGR of 6.2%

The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033 and the Worldwide Musculoskeletal Market…

NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program

Bristol Myers Squibb Company, et al. v. Xavier Becerra, et al. Bristol Myers Squibb Company, et al. v. Xavier Becerra,…

Bristol-Myers Squibb - Investors Are Too Long-Term Focused (NYSE:BMY)

Bristol-Myers Squibb faces challenges with patent expirations, but has long-term shareholder return potential. Read why BMY stock is a good investment.…

Bristol-Myers Squibb Is A Bargain Now

…

Is Bristol-Myers Squibbs Rich Dividend Yield Worth The Patent Cliff Correction Risk?

…

Bristol-Myers Squibb: Seriously Undervalued And Poised For An Inflection

…

Erste Schätzungen: Bristol-Myers Squibb vermeldet Zahlen zum jüngsten Quartal

Bristol-Myers Squibb wird voraussichtlich am 26.07.2024 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 30.06.2024 – vorstellen.Die Schätzungen…

Bristol-Myers Squibb: Time To Double Down

…

Is Bristol Myers Squibb Stock a Buy?

Does Bristol Myers have the potential to be a market-beating stock?…

Is Bristol Myers Squibb Stock a Buy? @themotleyfool #stocks $BMY

Does Bristol Myers have the potential to be a market-beating stock?…

Global Lenalidomide Drug Market Size To Worth USD 21.47 Billion By 2033 | CAGR Of 5.69%

The Global Lenalidomide Drug Market Size was Valued at USD 12.34 Billion in 2023 and the Worldwide Lenalidomide Drug Market…

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb

These two pharma stocks are beloved by income investors.…

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb

…

OrganoClick appoints Carin Eklund as new CFO

OrganoClick has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClicks finance and economics department…

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least (NYSE:BMY)

Bristol-Myers Squibb still elevated forward P/E indicates its unlikely to see an uptick anytime this year. Click here to read…

Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least

…

Evotec: Gute Nachrichten

Evotec verkündet einen Fortschritt in der Partnerschaft mit Bristol Myers Squibb.…

Evotec: Ein wichtiger Fortschritt innerhalb der Neurologie-Partnerschaft mit Bristol-Myers Squibb - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Evotec-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie der Evotec SE (ISIN: DE0005664809,…

EQS-News: Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt (deutsch)

Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec gibt Fortschritt in Neurologie-Partnerschaft mit…

Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)

…

Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference

…

Bristol Myers Squibb wins antitrust case against insurers regarding generics

…

Analyst Report: Bristol-Myers Squibb Co.

…

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

…

Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 (“ERISA”) (Brower Piven Release)

BALTIMORE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Lawsuits have been filed alleging that a number of large…

Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

…

[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult…

Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript

…

Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)

…

Biotech Reveals More From The Study That Boosted Shares 83%

The company is hoping to take on Bristol Myers Squibbs Camzyos, a treatment for obstructive HCM.…

Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma

The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake,…

Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?

Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock.…

If Youd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Heres How Much Youd Have Today

The answer isnt great, but theres still reason to like Bristol Myers Squibb.…